Consider lowering the dose of these agents when coadministered with FARXIGA Pooled safety data across 12 placebo-controlled clinical studies of glycemic control in adults with T2D 1 Adverse reactions reported in 2% of adults taking FARXIGA 10 mg (n=1193) vs placebo (n=1393) included female genital mycotic infections (6.9% vs 1.5%), nasopharyngitis (6.3% vs 6.2%), UTIs (4.3% vs 3.7%), back pain (4.2% vs 3.2%), increased urination (3.8% vs 1.7%), male genital mycotic infections (2.7% vs 0.3%), nausea (2.5% vs 2.4%), dyslipidemia (2.5% vs 1.5%), influenza (2.3% vs 2.3%), and discomfort with urination (2.1% vs 0.7%)
Additional analyses categorized the exposure of GLAs into incretin-based agents (i.e., DPP4is and GLP-1RAs), weight-loss effect agents (i.e., GLP-1RAs and SGLT2is), and newer GLAs (i.e., DPP4is, GLP-1RAs, and SGLT2is) (Supplemental Table 2)
The glucagon arm is the main pharmacological differentiator versus tirzepatide
PlexusDx provides advanced combination options tailored to individual metabolic profiles
